Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part I. In vivo studies

Leuk Res. 2004 Nov;28(11):1125-36. doi: 10.1016/j.leukres.2004.03.003.


Six patients with bcr-abl positive AML or chronic myelogenous leukemia in blast crisis (CML-BC) were treated with the IMP-dehydrogenase (IMPDH) inhibitor, Tiazofurin, in a Phase-II trial. Tiazofurin was given by IV infusion (2200-2700 mg/m2 per day) for up to 10 days. Leukemia blasts rapidly disappeared from the circulation of patients during treatment, while mature myeloid cells in the marrow increased in number. Although these hematologic responses were transient, persisting less than 3-4 weeks, our findings confirm that Tiazofurin has anti-leukemia activity. This drug warrants further study in combination regimens with other chemotherapeutic agents for the treatment of bcr-abl positive AML and CML-BC.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Enzyme Inhibitors / therapeutic use*
  • Female
  • Genes, abl*
  • Humans
  • IMP Dehydrogenase / antagonists & inhibitors*
  • Leukemia, Myeloid, Acute / drug therapy*
  • Male
  • Middle Aged
  • Ribavirin / analogs & derivatives*
  • Ribavirin / therapeutic use*
  • Treatment Outcome


  • Antineoplastic Agents
  • Enzyme Inhibitors
  • Ribavirin
  • IMP Dehydrogenase
  • tiazofurin